Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CAMP

CAMP4 Therapeutics (CAMP) Stock Price, News & Analysis

CAMP4 Therapeutics logo

About CAMP4 Therapeutics Stock (NASDAQ:CAMP)

Advanced Chart

Key Stats

Today's Range
$3.52
$4.67
50-Day Range
$0.40
$4.00
52-Week Range
$1.31
$12.30
Volume
58,479 shs
Average Volume
164,208 shs
Market Capitalization
$28.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50
Consensus Rating
Buy

Company Overview

CAMP4 Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

CAMP MarketRank™: 

CAMP4 Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 523rd out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CAMP4 Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CAMP4 Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about CAMP4 Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for CAMP4 Therapeutics are expected to grow in the coming year, from ($4.99) to ($2.89) per share.

  • Price to Book Value per Share Ratio

    CAMP4 Therapeutics has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for CAMP.
  • Dividend Yield

    CAMP4 Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CAMP4 Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CAMP.
    • Insider Buying vs. Insider Selling

      In the past three months, CAMP4 Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      33.60% of the stock of CAMP4 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Read more about CAMP4 Therapeutics' insider trading history.
    Receive CAMP Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for CAMP4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    CAMP Stock News Headlines

    $100 Trillion “AI Metal” Found in American Ghost Town
    Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
    See More Headlines

    CAMP Stock Analysis - Frequently Asked Questions

    CAMP4 Therapeutics Corporation (NASDAQ:CAMP) issued its quarterly earnings results on Tuesday, May, 13th. The Wireless communications provider reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.70) by $0.08. The Wireless communications provider earned $0.86 million during the quarter, compared to analysts' expectations of $0.10 million.

    Shares of CAMP4 Therapeutics reverse split on Friday, February 2nd 2024.The 1-23 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

    The following companies are subsidiaries of CAMP4 Therapeutics: LoJack, Gulfstream Telematics, SmartLink Radio Networks, CalAmp Wireless Networks Inc., Skybility, Boisen S.A., CalAmp Importation and Leasing of Tracking Equipment Ltd., and others.

    CAMP4 Therapeutics (CAMP) raised $75 million in an IPO on Friday, October 11th 2024. The company issued 6,820,000 shares at a price of $11.00 per share.

    Based on aggregate information from My MarketBeat watchlists, some other companies that CAMP4 Therapeutics investors own include Zimmer Biomet (ZBH), Union Pacific (UNP), Charter Communications (CHTR), NVIDIA (NVDA), PayPal (PYPL), MercadoLibre (MELI) and Meta Platforms (META).

    Company Calendar

    Last Earnings
    5/13/2025
    Today
    7/05/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Communications Equipment
    Current Symbol
    NASDAQ:CAMP
    Employees
    644
    Year Founded
    1981

    Price Target and Rating

    Average Stock Price Target
    $16.50
    High Stock Price Target
    $23.00
    Low Stock Price Target
    $8.00
    Potential Upside/Downside
    +1,049.8%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.17
    Research Coverage
    6 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    $650 thousand
    Price / Cash Flow
    N/A
    Book Value
    $3.13 per share
    Price / Book
    0.46

    Miscellaneous

    Free Float
    13,387,000
    Market Cap
    $28.93 million
    Optionable
    No Data
    Beta
    N/A

    Social Links

    5G Stocks: The Path Forward is Profitable Cover

    Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

    Get This Free Report

    This page (NASDAQ:CAMP) was last updated on 7/5/2025 by MarketBeat.com Staff
    From Our Partners